HX GROUP(SH:600851)2023-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥625.16 million, a decrease of 1.78% compared to ¥636.51 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥101.68 million, down 18.80% from ¥125.22 million in the previous year[21]. - The basic earnings per share for the first half of 2023 was ¥0.0842, representing a decline of 18.80% compared to ¥0.1037 in the same period last year[20]. - The net cash flow from operating activities decreased by 64.12%, amounting to approximately ¥3.73 million compared to ¥10.39 million in the previous year[21]. - The company reported a decrease of 14.33% in net profit after deducting non-recurring gains and losses, amounting to approximately ¥104.42 million compared to ¥121.88 million in the previous year[21]. - The company achieved operating revenue of CNY 625.16 million, a year-on-year decrease of 1.78%[28]. - Net profit for the period was CNY 101.68 million, down 18.80% year-on-year[28]. - The company reported a significant decrease in sales expenses, which fell to CNY 190,262,248.25 from CNY 241,573,821.60[97]. - The net profit for the first half of 2023 was CNY 99,833,267, a decrease of 21.7% from CNY 127,346,935 in the first half of 2022[102]. - The total comprehensive income for the first half of 2023 was CNY 187,323,767.30, compared to a loss of CNY 172,354,564.22 in the first half of 2022[102]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥5.12 billion, an increase of 3.88% from the previous year's end[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥3.84 billion, reflecting an increase of 3.56% compared to the previous year[21]. - The company's total liabilities amounted to CNY 969,910,430.35, compared to CNY 911,215,769.39, marking an increase of around 6.05%[91]. - Total assets increased to CNY 5,230,032,587.68, up from CNY 5,050,661,992.87 at the end of the previous period[95]. - The company's total liabilities are not explicitly stated but can be inferred from the total equity and assets figures[115]. Segment Performance - The pharmaceutical segment generated CNY 357.81 million in revenue, a decline of 7.05% year-on-year, with net profit of CNY 9.28 million, down 15.84%[28]. - The property leasing segment reported rental income of CNY 49.19 million, an increase of 7.40% year-on-year, with operating net profit of CNY 25.17 million, down 6.60%[31]. - The textile segment's revenue was CNY 84.98 million, a decrease of 19.47% year-on-year, with a net loss of CNY 2.23 million[32]. Cash Flow - The net cash flow from operating activities for the first half of 2023 was -25,697,515.58 RMB, compared to -22,729,508.26 RMB in the same period of 2022, indicating a decline of approximately 13.0%[108]. - Cash and cash equivalents at the end of the period increased to 508,902,217.10 RMB, up from 373,386,172.34 RMB in the previous year, representing a growth of about 36.2%[106]. - The net cash flow from investing activities was 126,372,977.82 RMB, an increase of 62.5% compared to 77,667,369.67 RMB in the first half of 2022[109]. Shareholder Information - Total number of ordinary shareholders as of the end of the reporting period is 65,429, with 33,754 A-share holders and 31,675 B-share holders[81]. - The largest shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 141,528,801 shares, representing 11.73% of total shares[83]. - The company has not reported any changes in share capital structure during the reporting period[80]. Environmental Compliance - The company is listed as a key pollutant discharge unit, with subsidiaries included in the environmental protection department's list[58]. - The company’s wastewater treatment standards have not exceeded the regulatory limits, indicating compliance with environmental standards[59]. - The company reported that particulate matter emissions from the workshop were below the standard limit of <120 mg/Nm3, indicating compliance with environmental regulations[61]. - The total nitrogen emissions from wastewater were measured at 4.357 mg/L, significantly below the regulatory limit of <30 mg/L[63]. - The company continues to monitor and ensure that all emissions remain within the regulatory limits, demonstrating a commitment to environmental responsibility[61]. Legal Matters - The company is actively following up on the litigation process regarding the equity exit lawsuit to protect its rights[48]. - The first-instance judgment in the creditor lawsuit against Baoding Haixin has been supported by the court, and the next step is to apply for the execution of the judgment[48]. - The company is preparing for a civil lawsuit initiated by China Construction Eighth Engineering Division regarding project settlement disputes, which is pending trial[48]. Strategic Initiatives - The company is actively disposing of low-efficiency assets to improve overall asset quality, with several subsidiaries being deregistered in 2023[33]. - The company is focusing on enhancing its core competitiveness in the pharmaceutical sector through increased R&D efforts[28]. - The company is transitioning its textile operations from a "production-oriented" model to a "R&D and trade-oriented" model[32]. Accounting Policies - The company's accounting policies comply with the relevant accounting standards, ensuring the accuracy and completeness of financial reporting[125]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[166]. - The company uses the weighted average method for inventory cost calculation, which includes raw materials, direct labor, and manufacturing expenses allocated under normal production capacity[187].